The Swiss agency that regulates new drugs has approved the application for a clinical trial with an experimental Ebola vaccine at the Lausanne University Hospital.
Swissmedic says the trial will be conducted on 120 volunteer participants with support from the U.N. World Health Organization.
Continue Reading Below
The agency said in a statement Tuesday that the trial continues a series that began in the United States, Britain and Mali, using a vaccine based on a genetically modified chimpanzee adenovirus.
The experimental vaccine is to be initially administered on healthy volunteers who will be sent as medical staff to fight the Ebola epidemic in West Africa.